Granules India Q2 Results: Stock rises after EBITDA surges, margin expands

For the September quarter of FY25, Granules India's net profit rose 35% year-on-year to ₹131 crore, compared with ₹97.2 crore in the same period last year.

Revenue grew 34.2% to ₹1,297 crore from ₹966.6 crore a year ago, while EBITDA increased 37% to ₹278 crore from ₹203.4 crore.

The company's EBITDA margin improved slightly to 21.4%, up from 21% in the year-ago quarter.

The company's net debt stood at INR 1,024 crore and Net debt to EBITDA at 0.98x.

"We are delighted to deliver a resilient financial performance with healthy growth in both revenue and profitability. The improvement in EBITDA and PAT reflects our continued focus on operational excellence, disciplined execution, and the strength of our governance. Our ongoing investments in R&D and talent underscore our commitment to innovation and long-term value creation. Our peptides CDMO platform through Ascelis, anchored in the legacy of Senn Chemicals in Switzerland, is steadily gaining visibility, with renewed customer interest and promising new discussions underway," said Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India.

Following the results, shares of Granules India were trading 2.3% higher at ₹554.4. The stock is down 7% so far in 2025.